DOCSLIB.ORG

Hyperthyroidism Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hyperthyroidism Treatment Thyrotoxicosis (hyperthyroidism) Introduction: Thyrotoxicosis is any syndrome caused by excess thyroid hormone and can be related to excess hormone production (hyperthyroidism). Pathophysiology: Thyrotoxicosis results when tissues are exposed to excessive levels of T4, T3, or both. Hyperthyroidism, which is one cause of thyrotoxicosis, refers to overproduction of thyroid hormone by the thyroid gland. TSH-secreting pituitary tumors release biologically active hormone that is unresponsive to normal feedback control. Graves’ disease is the most common cause of hyperthyroidism; it results from the action of thyroid-stimulating antibodies (TSAb) directed against the thyrotropin receptor on the surface of thyroid cell. Clinical presentation: Subtle and slowly progressive, patient may seek medical attention only after long period of thyrotoxicosis or owing to an acute complication such as atrial fibrillation. *Symptoms: Nervousness, anxiety, palpitations, emotional lability, easy fatigability, heat intolerance, weight loss concurrent with increased appetite, increased frequency of bowel movements, proximal muscle weakness (noted on climbing stairs or arising from a sitting position), and scanty or irregular menses in women. *Sign: Physical signs include warm, smooth, moist skin and unusually fine hair; onycholysis, lid lag, tachycardia at rest, occasional gynecomastia in men; fine tremor of the protruded tongue and outstretched hands; and hyperactive deep tendon reflexes. Thyroid storm is a life-threatening medical emergency characterized by decompensated thyrotoxicosis, high fever (often>39.4°C [103°F]), tachycardia, tachypnea, dehydration, delirium, coma, nausea, vomiting, and diarrhea. Precipitating factors include infection, trauma, surgery, radioactive iodine (RAI) treatment, and withdrawal from antithyroid drugs. Diagnosis: The diagnosis of hyperthyroidism is based upon thyroid function test. Low TSH level (less than 0.5 mIU /L or µIU /mL) signifies thyrotoxicosis. FT4 is elevated in overt hyperthyroidism but may be normal in mild hyperthyroidism. Increased radioiodine uptake in the thyroid indicates increased hormone production by the thyroid gland. Almost all patients with graves’ disease will have positive TSHR-SAbs and positive anti-TPOAbs. Low RAIU indicates excess thyroid hormone not by thyroid gland hyperfunction, this may see in painful thyroiditis, painless thyroiditis, Struma ovarii and follicular cancer. Treatment: *Goals of treatment: 1.Eliminate excess thyroid hormone. 2.Minimize symptoms and long-term consequences. 3.Provide individualized therapy based on the type and severity of disease, patient age and gender, existence of nonthyroidal conditions, and response to previous therapy. Nonpharmacology: . Surgical removal of the thyroid gland should be considered in patients with a large gland (>80 g), severe ophthalmopathy, or lack of remission on antithyroid drug treatment. If thyroidectomy is planned, propylthiouracil (PTU) or methimazole is usually given until the patient is biochemically euthyroid (usually 6– 8 weeks), followed by addition of iodides (500 mg/day) for 10–14 days before surgery to decrease vascularity of the gland. Levothyroxine may be added to maintain the euthyroid state while thionamides are continued. Complication of surgery: 1.Hypothyroidism, 2.Recurrent laryngeal nerve injury, 3.Airway obstruction, 4.Wound infection. Pharmacology: THIOUREAS (THIONAMIDES): o Propylthiouracil(PTU) and Methimazole *Mechanism of action PTU and methimazole block thyroid hormone synthesis by inhibiting the peroxidase enzyme system of the thyroid, preventing oxidation of trapped iodide and by inhibiting coupling of MIT and DIT to form T4 and T3. PTU (but not methimazole) also inhibits peripheral conversion of T4 to T3. *Initial dose Usual initial doses include PTU 300 to 600 mg daily (usually in three or four divided doses) or methimazole 30 to 60 mg daily given in three divided doses. Evidence exists that both drugs can be given as a single daily dose. *Maintenance dose . Typical daily maintenance doses are PTU 50 to 300 mg and methimazole 5 to 30 mg. Continue therapy for 12 to 24 months to induce long-term remission. Improvement in symptoms and laboratory abnormalities should occur within 4 to 8 weeks, at which time a tapering regimen to maintenance doses can be started. *Monitoring Monitor patients every 6 to 12 months after remission. *Adverse effects . Major adverse effects include agranulocytosis (with fever, malaise, gingivitis, or pharyngeal infection, aplastic anemia, lupus-like syndrome, polymyositis, GI intolerance, hepatotoxicity, and hypoprothrombinemia. Minor adverse reactions include pruritic maculopapular rashes, arthralgias, fever, and benign transient leukopenia (white blood cell count <4000/mm3 or 4 × 109/L). Because of the risk of hepatotoxicity dont use the PTU as first line therapy unless in 1- First trimester of pregnancy 2- Intolerance to methimazole 3- Thyroid storm IODIDES *Mechanism of action . Acutely blocks thyroid hormone release, inhibit thyroid hormone biosynthesis by interfering with intrathyroidal iodide use, and decreases size and vascularity of the gland. *Dosage form Potassium iodide is available as a saturated solution (SSKI, 38 mg iodide per drop) or as Lugol`s solution, containing 6.3 mg of iodide per drop. *Dose: Typical starting dose of SSKI is 3 to 10 drops daily (120–400 mg) in water or juice. When used to prepare a patient for surgery, it should be administered 7 to 14 days preoperatively. Symptom improve occur within 2-7 days of initial therapy. *Adverse effects: Hypersensitivity reactions (skin rashes, drug fever, rhinitis, conjunctivitis), salivary gland swelling, “iodism” (metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes stomach upset and diarrhea), and gynecomastia. Iodides are often used as adjunctive therapy to prepare a patient with Graves’ disease for surgery before 7-14 days. SSKI should not be used before but rather 3 to 7days after RAI treatment so the RAI can concentrate in the thyroid. ADRENERGIC BLOCKERS o Propranolol and Nadolol *β-Blockers are used to ameliorate thyrotoxic symptoms such as palpitations, anxiety, tremor, and heat intolerance, they have no effect on peripheral thyrotoxicosis or prevent thyroid storm. *β-Blockers are usually used as adjunctive therapy with antithyroid drugs and RAI or iodide. The only conditions for which β-blockers are primary therapy for thyrotoxicosis are those associated with thyroiditis. *Initial Dose: -Propranolol dose 20 to 40 mg orally four times daily is effective for most patients (heart rate <90 beats/min). -Younger or more severely toxic patients may require 240 to 480 mg/day. *Contraindications: 1.Decompensated heart failure unless it is caused solely by tachycardia. 2.Sinus bradycardia. 3.Concomitant therapy with monoamine oxidase inhibitors or tricyclic antidepressants. 4.Patients with spontaneous hypoglycemia. Centrally acting sympatholytic (eg, clonidine) and calcium channel antagonists (eg, diltiazem) may be useful for symptom control when contraindications to β-blockade exist. *Adverse effects: Side effects include nausea, vomiting, anxiety, insomnia, lightheadedness, bradycardia, and hematologic disturbances. RADIOACTIVE IODINE (RAI): o Sodium iodide–131 is an oral liquid that concentrates in the thyroid and initially disrupts hormone synthesis by incorporating into thyroid hormones and thyroglobulin *USES: Agent of choice for Graves’ disease, toxic autonomous nodules, and toxic multinodular goiters. *Dose: -The goal of therapy is to destroy overactive thyroid cells, and a single dose of 4000 to 8000 rad (40–80 Gy) results in a euthyroid state in 60% of patients at 6 months or sooner. -A second dose of RAI should be given 6 months after the first RAI treatment if the patient remains hyperthyroid. -Patients with cardiac disease and elderly patients are often treated with thionamides prior to RAI ablation because thyroid hormone levels transiently increase after RAI treatment due to release of preformed thyroid hormone. -Antithyroid drugs are not routinely used after RAI because their use is associated with a higher incidence of posttreatment recurrence or persistent hyperthyroidism. -If iodides are administered, they should be given 3 to 7 days after RAI to prevent interference with uptake of RAI in the thyroid gland. *Adverse effects: Hypothyroidism commonly occurs months to years after RAI. The acute, short- term side effects include mild thyroidal tenderness and dysphagia. *Contraindication: Pregnancy is an absolute contraindication to use of RAI. PREGNANCY - PTU is considered the drug of choice during the first trimester of pregnancy, with the lowest possible doses used to maintain the maternal T4 level in the high-normal range. - To prevent fetal goiter and suppression of fetal thyroid function, PTU is usually prescribed in daily doses of 300 mg or less and tapered to 50 to 150 mg daily after 4 to 6 weeks. - PTU doses of less than 200 mg daily are unlikely to produce fetal goiter. -During the second and third trimesters, when the critical period of organogenesis is complete, MMI is thought to be the drug of choice because of the greater risk of hepatotoxicity with PTU. Neonatal and Pediatric Hyperthyroidism -Some babies of hyperthyroid mothers will be hyperthyroid due to placental transfer of TSAbs, which stimulates thyroid hormone production in utero and postpartum; this is likely if the maternal TSAb titers were quite
Load more

Recommended publications
  • Optimal 131I Therapy of Thyrotoxicosis SNMMI Annual Meeting, 6/26/2018
    Optimal 131I Therapy of Thyrotoxicosis SNMMI Annual Meeting, 6/26/2018 I Love What I do, i.e. Nuclear Medicine … RADIOACTIVE IODINE THERAPY FOR No other relevant disclosures HYERTHYROIDISM Mark Tulchinsky, MD, FACNM, CCD or conflicts of interest Professor of Radiology and Medicine Division of Nuclear Medicine Penn State University Hospital Radioactive Iodine (RAI) Learning Objectives Administration for Graves’ • Treatment Options Disease: Birthplace of • Medications Radiotheranostics • Surgery Saul Hertz, M.D. • 131I Treatment (RAIT) (April 20, 1905 – July 28, 1950) • The first to study RAI in an • Graves’ Disease w/o Orbitopathy animal model of hyperthyroidism • Graves’ Disease with Orbitopathy • March 31st, 1941, at the age of 35 y, administered • Toxic Adenoma the first RAI treatment • Multinodular Toxic Goiter (RAIT) to a patient with Grave’s disease • Intermittent (recurrent) Thyroiditis • The first to use RAI uptake to inform RAIT, i.e. • Amiodarone Thyrotoxicosis radiotheranostic principle Therapeutic Options for Productive Conditions Amenable to RAIT Hyperthyroidism Condition Etiology • Antithyroid Drug therapy (ATDT) Graves’ disease (~80%) TSH-R-Ab stimulation of thyrocyte Symptomatic control with beta blockers Toxic Multinodular Goiter mutation → TSH-R-Ab activation → Toxic Adenoma autonomous function Thioureas, aka Thionamides, Anti- Hashimoto’s Thyroiditis in autoimmune disease - a variety of Thyroid Drugs (ATD’s) productive phase (“Hashi- cell- and antibody-mediated toxicosis”, overlaps Graves’) immune processes Corticosteroids
    [Show full text]
  • The Radiochemistry of Bismuth
    NAS-NS-3061 RA OFBISMUTH NUCLEAR SCIENCE SERIES National Academy of Sciences - National Research Council Published by Technical Information Center ENERGY RESEARCH AND DEVELOPMENT ADMINISTRATION COMMITTEE ON NUCLEAR SCIENCE John Huizenga, Chairman, Nuclear WrUcture Re=arch Laboratory Thomas A. Tombrello, Vice Chairman, California institute of T=hnology C. K. Reed, Executive Secretary,Netional Academy of Sciences Lowell M. Bollinger, Argonne Nationel Laboratow Peggy Dyer, UnivarsiW of Washington Rusaall Heath, Aerojet Nuclear Co., Inc. Roy K. Middlaton, University of Pennsylvania 1: Lon Morgan, Columbie Scientific Industries G. Davis O’Kelley, Oek Ridge National Laboratow G. C. Phillips, Rice University Henry N. Wagner, Jr., The Johns Hopkins Medial Institutions Joseph Wen~, Brookhaven National Laboratory Sheldon’ Wolff, University of California Chien-Shiung Wu, Columbia Univar?@ Alexander Zuckar, Oak Ridga National Laborato~ Liaison Members William S. Rodney, National science Foundation George L. ROWS, Energy Research and Development Admini-ration SUBCOMMITTEE ON RAD1OCHEMISTRY G. Davis O’Kelley, Chairmsrr, Oak Ridge National Laboratory Glen E. Gordon, UnivwsiW of Maryler& ‘“- ,-. Rolfa H. Hw*r, Rutgers Univemity John A. Miskel, Lawrence Livermore LaboratoW Harold A. O’Brien, Jr., Los Alamos Scientific Laboratory Richard W. Perkins. Bettafle Pacific Northwest Laboratories Andrew F. Stehney, Argonne National Laboratory Kurt Wotfsbarg, Los Alanros Scientific Laboratow LiaisonMembers ~ John L. Burnatte, Energy Research and Davelopmant Administration FTed Findeis, National Scienca Foundation i.,.~.. Radiochemistry of Bismuth Kashinath S. Bhatki Tata Instituteof Fundamental Research Homi Bhabha Road, Bombay 400005 and Bhabha Atomic ResearchC-entre Trornbay,Bombay 400085 (India) Prepared for Subcommittee on Radiochemistry National Academy of Sciences - Natiorial Research Council IssuanceDate:September 1977 Published by Technical 1nform,ation center ENERGY RESEARCH AND DEVELOPMENT ADMINISTRATION Price$4.75.Availablefrom: NationalTechnicalInformationservice U.
    [Show full text]
  • Pesticides with Potential Thyroid Hormone-Disrupting Effects: a Review of Recent Data Michelle Leemans, Stephan Couderq, Barbara Demeneix, Jean-Baptiste Fini
    Pesticides With Potential Thyroid Hormone-Disrupting Effects: A Review of Recent Data Michelle Leemans, Stephan Couderq, Barbara Demeneix, Jean-Baptiste Fini To cite this version: Michelle Leemans, Stephan Couderq, Barbara Demeneix, Jean-Baptiste Fini. Pesticides With Po- tential Thyroid Hormone-Disrupting Effects: A Review of Recent Data. Frontiers in Endocrinology, Frontiers, 2019, 10, pp.743. 10.3389/fendo.2019.00743. hal-02415200 HAL Id: hal-02415200 https://hal.archives-ouvertes.fr/hal-02415200 Submitted on 26 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. REVIEW published: 09 December 2019 doi: 10.3389/fendo.2019.00743 Pesticides With Potential Thyroid Hormone-Disrupting Effects: A Review of Recent Data Michelle Leemans*, Stephan Couderq, Barbara Demeneix and Jean-Baptiste Fini* Muséum National d’Histoire Naturelle, CNRS UMR 7221, Laboratoire Physiologie moléculaire de l’adaptation, Paris, France Plant Protection Products, more commonly referred to as pesticides and biocides, are used to control a wide range of yield-reducing pests including insects, fungi, nematodes, and weeds. Concern has been raised that some pesticides may act as endocrine disrupting chemicals (EDCs) with the potential to interfere with the hormone systems of non-target invertebrates and vertebrates, including humans.
    [Show full text]
  • Synthesis and Nucleophilic Reactions of Bifunctional Thiourea S,S,S-Trioxides Dan Webb '89 Illinois Wesleyan University
    Illinois Wesleyan University Digital Commons @ IWU Honors Projects Chemistry 1989 Synthesis and Nucleophilic Reactions of Bifunctional Thiourea S,S,S-Trioxides Dan Webb '89 Illinois Wesleyan University Recommended Citation Webb '89, Dan, "Synthesis and Nucleophilic Reactions of Bifunctional Thiourea S,S,S-Trioxides" (1989). Honors Projects. Paper 30. http://digitalcommons.iwu.edu/chem_honproj/30 This Article is brought to you for free and open access by The Ames Library, the Andrew W. Mellon Center for Curricular and Faculty Development, the Office of the Provost and the Office of the President. It has been accepted for inclusion in Digital Commons @ IWU by the faculty at Illinois Wesleyan University. For more information, please contact [email protected]. ©Copyright is owned by the author of this document. • SynthesIs and Nucleophilic ReactIons of BIfunctional Thiourea S,S,S-TrIoxldes Dan Webb A ThesIs SubmItted In PartIal FulfIllment of the Requirements for Research Honors In ChemIstry at IllInois Wesleyan UnIversIty 1989 • ABSTRACT: The synthesis of bifunctional thioureas and the corresponding thiourea S,S,S-trioxides has been examined. Two methods for the synthesis of the bisthioureas were employed. One involved the treatment of a diamine with si1 icon tetraisothiocyanate in benzene. The second involved treatment of the amine with ammonium thiocyanate in dilute acid. This latter synthesis was superior because of the ease of its use, the high yields obtained, and the purity of the products. Though this synthesis worked well for the preparation of phenylene-l,4-bis(thiourea), it yielded only bisthiocyanate salts in the syntheses of al iphatic thioureas. The oxidation of the bisthioureas was carried out using peracetic acid or hydrogen peroxide to give the corresponding thiourea S,S,S-trioxides.
    [Show full text]
  • Comparative Pharmacotherapy of Thyroid
    ical C eut are ac & m H Mickael, J Pharma Care Health Sys 2015, S3 r e a a h l 10.4172/2376-0419.S3-002 t DOI: P h f S o y Journal of l s a t n e r m u s o J ISSN: 2376-0419 Pharmaceutical Care & Health Systems ReviewResearch Article Article OpenOpen Access Access Comparative Pharmacotherapy of Thyroid Diseases in Dogs and Cats--- What Should the Retail Pharmacist Filling Pet Prescriptions Understand? Marina Mickael, Eric Morris, Mollie M Roush and Inder Sehgal* Marshall University School of Pharmacy, West Virginia, USA Abstract Community pharmacies are increasingly receiving prescriptions from veterinarians for dogs and cats to receive human medications. However, retail pharmacists are not routinely trained in relevant aspects of veterinary-specific pharmacotherapy, such as, signs of improvement, time to improvement, drug administration techniques and potential adverse effects. Thyroid diseases in dogs and cats are treated with human-approved drugs that may be referred to pharmacies. Hypothyroidism is far more frequent in dogs, while hyperthyroidism is far more frequent in cats. Important comparative aspects of canine hypothyroidism pharmacotherapy can be summarized as follows: 1) Canine hypothyroid disease is similar to Hashimoto’s thyroiditis in humans in many of its signs and is treated using levothyroxine; 2) The doses of levothyroxine given to dogs are strikingly higher than in people; 3) A reasonable therapeutic goal is resolution of symptoms in two weeks to two months and a normal total T4 value (≈0.4-3.7 µg/dL). Important comparative
    [Show full text]
  • 1999 Handbook
    The Australian Short Course on Intensive Care Medicine 1999 Handbook The Australian Short Course on Intensive Care Medicine 1999 Handbook Editor L.I.G. Worthley Published in 1999 by The Australasian Academy of Critical Care Medicine Department of Critical Care Medicine Flinders Medical Centre, Bedford Park South Australia 5042 ISSN 1327-4759 1999 The Australasian Academy of Critical Care Medicine Requests to reproduce original material should be addressed to the publisher. Printed by Gillingham Printers Pty Ltd 153 Holbrooks Road Underdale South Australia 5032 CONTENTS Page Chapter 1. Cardiac anatomy 1 Chapter 2. Physiology of myocardial contractility 7 Chapter 3. Cardiac output and oxygen delivery 25 Chapter 4. The autonomic nervous system 49 Trainee Presentations 67 Index 131 iii iv 1999 SHORT COURSE PROGRAMME March 22nd 23rd 24th 25th 26th FMC QEH RAH RAH FMC 0815 Travel to Travel to Travel to FMC QEH FMC 0900 Lecture Interactive Lecture Lecture Lecture Examination of Management of Diagnosis & ] the critically ill Clinical adult neurotrauma of nosocomial Acute liver patient vignettes J.M pneumonia failure L W. L.W. M.C. A.H 1015 Lecture Interactive Clinical cases Interactive Interactive Biochemistry, J.M M.C In defence of Blood gases, ---------------------- Clinical cases Acid base & Blood Pressure Bacteriology Trauma vignettes Blood gases A.B B.V. B.G. M.F L.W 1130 Clinical cases Interactive Lecture Interactive Interactive A.V A.H B.V L.W --------------------- X-rays Organ donation Pathology, X Presentat’ns Respiratory rays, ECG’s assistance in airflow L.W. R.Y M.F L. W obstruction A.B 1245 Lunch Travel to WCH 1400 Interactive Lecture Lecture Lecture Common ECG's Outcome ARDS update paediatric Prediction ICU problems L.W J.M M.C N.M 1515 Lecture Interactive Clinical cases Short questions Understanding M.F R.Y Fluid & Asthma and ---------------------- N.M.
    [Show full text]
  • A Literature Review of the State of the Science Regarding Species
    A LITERATURE REVIEW OF THE CURRENT STATE OF THE SCIENCE REGARDING SPECIES DIFFERENCES IN THE CONTROL OF, AND RESPONSE TO, THYROID HORMONE PERTURBATIONS. PART 1: A HUMAN HEALTH PERSPECTIVE Report No: RSA/ECPA001_THYROID Report prepared for Sponsor: European Crop Protection Association Prepared by: Regulatory Science Associates Regulatory Science Ltd1 Kip Marina Inverkip Renfrewshire PA16 0AS APRIL 2018 1 Regulatory Science Ltd is a registered company in England and Wales. Registered office address: c/o Dafferns LLP, One Eastwood, Harry Weston Road, Binley Business Park, Coventry CV3 2UB Company Registration No. 6233406 VAT No. 907 7657 89 A LITERATURE REVIEW OF THE CURRENT STATE OF THE SCIENCE REGARDING SPECIES DIFFERENCES IN THE CONTROL OF, AND RESPONSE TO, THYROID HORMONE PERTURBATIONS. PART 1: A HUMAN HEALTH PERSPECTIVE STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS No claim of confidentiality, on any basis whatsoever, is made for any information contained in this document. I acknowledge that information not designated as within the scope of FIFRA §10(d)(1)(A), (B), or (C) and which pertains to a registered or previously registered pesticide is not entitled to confidential treatment and may be released to the public, subject to the provisions regarding disclosure to multinational entities under FIFRA 10(g). Sponsor: Submitter: ________________________________ Date: ________________________ Typed name of signer: _______________________ Typed name of company: _____________________________ Regulatory Science Ltd: Nov 2017 Report: RSA/ECPA001-THYROID Prepared for: ECPA Page 2 of 85 A LITERATURE REVIEW OF THE CURRENT STATE OF THE SCIENCE REGARDING SPECIES DIFFERENCES IN THE CONTROL OF, AND RESPONSE TO, THYROID HORMONE PERTURBATIONS. PART 1: A HUMAN HEALTH PERSPECTIVE STATEMENT OF COMPLIANCE WITH GOOD LABORATORY PRACTICE STANDARDS This report is a review of existing data.
    [Show full text]
  • Antithyroid Drug Therapy
    5 179 H B Burch and D S Cooper Antithyroid drug therapy: 179:5 R261–R274 Review 70 years later ANNIVERSARY REVIEW Antithyroid drug therapy: 70 years later Henry B Burch1 and David S Cooper2 Correspondence 1National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, should be addressed Maryland, USA and 2Division of Endocrinology, Diabetes, and Metabolism, The Johns Hopkins University School of to D S Cooper Medicine, Baltimore, Maryland, USA Email [email protected] Abstract The thionamide antithyroid drugs were discovered in large part following serendipitous observations by a number of investigators in the 1940s who found that sulfhydryl-containing compounds were goitrogenic in animals. This prompted Prof. Edwin B Astwood to pioneer the use of these compounds to treat hyperthyroidism in the early 1940s and to develop the more potent and less toxic drugs that are used today. Despite their simple molecular structure and ease of use, many uncertainties remain, including their mechanism(s) of action, clinical role, optimal use in pregnancy and the prediction and prevention of rare but potentially life-threatening adverse reactions. In this review, we summarize the history of the development of these drugs and outline their current role in the clinical management of patients with hyperthyroidism. European Journal of Endocrinology (2018) 179, R261–R274 History Prior to the 1940s, surgery was the only treatment for University School of Medicine, the Mackenzies (2) European Journal European of Endocrinology hyperthyroidism. In 1942, Edwin B Astwood began a series and Richter et al. (3). Both groups showed that certain of investigations at Harvard and later at Tufts Medical substances (sulfaguanidine and phenylthiourea, Schools that would ultimately lead to the development respectively) were goitrogenic.
    [Show full text]
  • Effect of Goitrogenic Materials on Thyroidal Activity and Feedlot Performance of Ruminants
    EFFECT OF GOITROGENIC MATERIALS ON THYROIDAL ACTIVITY AND FEEDLOT PERFORMANCE OF RUMINANTS by Arthur Phillip Raun A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of DOCTOR OF PHILOSOPHY Major Subject: Animal Nutrition Approved: Signature was redacted for privacy. In Charge of Majo Work Signature was redacted for privacy. Signature was redacted for privacy. I --- liege Iowa State College 1958 11 TABLE OF CONTENTS Page INTRODUCTION 1 REVIEW OF LITERATURE 3 Natural Goitrogens 3 Isolated Svntnetic Goitrogens 6 Mode of Action of Goitrogenic Compounds 9 Goitrogen Feeding Trials 17 Thyroid Activity 95 EXPERIMENTAL P9 Thyroid Activity 29 Metabolic Rate 34 Designs and Feedlot Methods 49. Lamb Tapazole Thyroid Activity Experiment .... 51 Steer Tapazole Experiment Measuring Thyroid Activity 53 Lamb Tapazole Feeding Experiment 54 Steer Tapazole Feeding Experiments 56 Carcass Quality 59 Growth Hormone and Thyrotrophic Hormone Assay . 60 RESULTS 65 Effect of Thiouracil on Thyroid Activity and Feedlot Performance of Steers 65 Effect of Tapazole on Thyroid Activity of Steers. 77 Effect of Different Levels of Tapazole on Thyroid Activity and Metabolic Rate of Lambs. 80 Effect of Different Levels of Tapazole and Stilbestrol on Feedlot Performance, Carcass Quality end Thyroid /."eight of Lambs 89 Effect of Different Levels of Tapazole on Feedlot Performance, Carcass Quality, and Thyroid Activity in Steers from Experiment 639. 97 Effect of Prolonged Administration of Different Levels of Tapazole and Stilbestrol in Cattle Feeding Experiment 641 110 Effect of Different Levels and Feeding Methods of Tapazole in Cattle Feeding Experiment 642. 12? Effect of Tapazole Treatments on Weight and Growth and Thyrotrophic Hormone Content of Bovine Anterior Pituitary 131 ill Ppge DISCUSSION 154 SUGARY 142 LITERATURE CITED 144 ACKNOWLEDGEMENTS 152 APPENDIX 153 1 INTRODUCTION Many goitrogenic materials have been tested as agents to promote fattening In ruminants, swine and poultry.
    [Show full text]
  • Synthesis of Aliphatic Bis(Thioureas)
    Illinois Wesleyan University Digital Commons @ IWU Honors Projects Chemistry 1991 Synthesis of Aliphatic Bis(Thioureas) Donald G. McEwen IV '91 Illinois Wesleyan University Follow this and additional works at: https://digitalcommons.iwu.edu/chem_honproj Part of the Chemistry Commons Recommended Citation McEwen IV '91, Donald G., "Synthesis of Aliphatic Bis(Thioureas)" (1991). Honors Projects. 26. https://digitalcommons.iwu.edu/chem_honproj/26 This Article is protected by copyright and/or related rights. It has been brought to you by Digital Commons @ IWU with permission from the rights-holder(s). You are free to use this material in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This material has been accepted for inclusion by faculty at Illinois Wesleyan University. For more information, please contact [email protected]. ©Copyright is owned by the author of this document. • Synthesis of Aliphatic Bis(Thioureas) Donald G. McEwen, IV A Paper Submitted in Partial Fufillment of the Requirements for Honors Research and Chemistry 499 at Illinois Wesleyan University 1991 • 11 Approval Page Research Honors SYNTHESIS OF ALIPHATIC BIS(THIOUREAS) Presented by Donald G. McEwen, IV Associate Associate Associate Illinois Wesleyan University 1991 • 111 Acknowledgments Serendipitously, I was given the opportunity to conduct undergraduate research. In doing so, I have run in to many problems. Thus, I would like to thank all those who have helped me with those problems: Dr.
    [Show full text]
  • Antithyroid Drugs
    Iranian Journal of Pharmaceutical Research (2019), 18 (Special Issue): 1-12 DOI: 10.22037/ijpr.2020.112892.14005 Received: December 2019 Accepted: December 2019 Review Paper Antithyroid Drugs Hengameh Abdi, Atieh Amouzegar and Fereidoun Azizi* Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Abstract The thionamide drugs, i.e. carbimazole and its metabolite methimazole (MMI), and propylthiouracil (PTU) have extensively been used in the management of various forms of hyperthyroidism over the past eight decades. This review aims to summarize different aspects of these outstanding medications. Thionamides have shown their own acceptable efficacy and even safety profiles in treatment of hyperthyroidism, especially GD in both children and adults and also during pregnancy and lactation. Of the antithyroid drugs (ATDs) available, MMI is the preferred choice in most situations taking into account its better efficacy and less adverse effects accompanied by once-daily dose prescription because of a long half-life and similar cost. Considering the more severe teratogenic effects of MMI, PTU would be the selected ATD for treatment of hyperthyroidism during pre-pregnancy months and the first 16 weeks of gestation. Recent studies have confirmed the efficacy and safety of long-term MMI therapy with low maintenance doses for GD and toxic multinodular goiter. Despite the long-term history of ATD use, there is still ongoing debate regarding their pharmacology and diverse mechanisms of action, viz. their immunomodulatory effects, and mechanisms and susceptibility factors to their adverse reactions. Keywords: Antithyroid; Thionamide; Methimazole; Propylthiouracil; Graves; Hyperthyroidism. Introduction agents in hyperthyroid patients being reported 1-2 years later (4, 5).
    [Show full text]
  • Identifying and Treating Thyroid Storm and Myxedema Coma in the Emergency Department Mills L
    Years Improving Patient Care August 2009 Identifying And Treating Volume 11, Number 8 Thyroid Storm And Myxedema Authors Lisa Mills, MD Director, Emergency Medicine Ultrasound, Associate Professor, Coma In The Emergency Emergency Medicine, Louisiana State University at New Orleans, New Orleans, LA Stephen Lim, MBBS Department Staff Physician, Department of Emergency Medicine, Leonard J. Chabert Medical Center, Houma, LA Case #1: A 65-year-old woman is brought to the emergency department Peer Reviewers (ED) with altered level of consciousness and hypotension. Her neighbor Michael S. Radeos, MD, MPH found her on the kitchen floor. He checked on her because he hadn’t seen her Assistant Professor of Emergency Medicine, Weill Medical for 3 days. The patient is unable to provide any verbal history. Her vital College of Cornell University, New York, NY signs are respiratory rate of 10 respirations per min, blood pressure of 90/60 Corey M. Slovis, MD, FACP, FACEP mm Hg, temperature 35°C (95°F), and heart rate 50 beats per min. On Professor and Chair, Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN physical examination, you see an obtunded woman in no apparent distress. CME Objectives You note a well-healed surgical scar on her anterior neck and that her left Upon completion of this article, you should be able to: leg is shortened and externally rotated. The differential diagnosis of the 1. Identify presenting signs and symptoms of a thyroid crisis. presentation is long and complex, and you keep wondering if that scar on 2. Discuss the treatment of myxedema coma.
    [Show full text]